Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Mi, Ze; Zhang, Yunshu; Feng, Zhichao; Liu, Jiahao; Wu, Jianmin; Tan, Hongpei; Ma, Xiaoqian; Liu, Zhenguo; Rong, Pengfei
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 50:Issue 1(2022)
• Page Start: 301
• Page End: 309
• Publication Date: 2022-12-31
• Subjects: PD-1/PD-L1 inhibitors -- CTLA-4 inhibitors -- combination therapy -- treatment-related adverse events; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2022.2131354
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Aim: PD-1/PD-L1 inhibitors in combination with CTLA-4 inhibitors are being tested in a number of ongoing clinical trials. As a result, it is critical to fully comprehend the toxicity characteristics of adverse events in combination therapy. This study aims to extensively compare the incidences and ORs of treatment-related adverse events between two combination strategies. Methods: The eligible articles were searched from PubMed, EMBASE and Cochrane databases for studies published between 1 January 2010 and 1 May 2021, investigating PD-1/PD-L1 inhibitors plus CTLA-4 inhibitor-based combined clinical therapies. The mean incidences and pooled ORs of all-grade and grade 3 or higher adverse events were calculated by random-effects model using Stata 12.1 . Heterogeneity between studies was assessed with I 2 statistics and Chi square-based Q statistic. The overall risk of bias was assessed by Review Manager 5.3 . Results: A total of 26 eligible studies of 3607 patients were selected; 2852 patients developed at least one all-grade adverse event. PD-L1 inhibitors plus CTLA-4 inhibitors regimen (incidence 0.67, 95% CI: 0.57–0.77) had marked advantage over PD-1 inhibitors plus CTLA-4 inhibitors regimen (incidence 0.89, 95% CI: 0.86–0.93). Conclusion: PD-L1 inhibitors plus CTLA-4 inhibitors shows better safety in treatment-related adverse events than PD-1 inhibitors plus CTLA-4 inhibitors.